Effectiveness of sitagliptin in Asian Indian patients with type 2 diabetes - An Indian tertiary diabetes care center experience

Diabetes Technology and Therapeutics

Volumn 13, Issue 1, 2011, Pages 27-32

  Sudhakaran, Chidambarann ^a   Kishore, Utkal ^a   Anjana, Ranjit Mohan ^a   Unnikrishnan, Ranjit ^a   Mohan, Viswanathan ^a  

^a MADRAS DIABETES RESEARCH FOUNDATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN GLARGINE; LIPID; METFORMIN; METFORMIN PLUS PIOGLITAZONE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SITAGLIPTIN; SULFONYLUREA;

ACUTE PANCREATITIS; ADD ON THERAPY; ARTICLE; ASIAN; BODY WEIGHT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COUGHING; DIARRHEA; DIET RESTRICTION; DRUG DOSE TITRATION; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INDIAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHINORRHEA; SIDE EFFECT; SINGLE DRUG DOSE; TERTIARY HEALTH CARE; WEIGHT GAIN; WEIGHT REDUCTION;

BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; INDIA; INSULIN; MALE; MIDDLE AGED; PYRAZINES; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TRIAZOLES; TRIGLYCERIDES;

EID: 78650628953     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2010.0120     Document Type: Article

References (37)

1. Unwin N, Whiting D, Gan D, Jacqmain O, Ghyoot G, eds. IDF Diabetes Atlas, 4th ed. Brussels: International Diabetes Federation, 2009:11-13.
2. Mohan V, Venkatraman JV, Pradeepa R: Epidemiology of cardiovascular disease in type 2 diabetes: The Indian scenario. J Diabetes Sci Technol 2010;4:158-170.
3. Shaw JE, Sicree RA, Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
5. Gaede P, Vedel P, Parving HH, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet 1999;353:617-622.
6. Narayan KM, Gregg EW, Engelgau MM, Moore B, Thompson TJ, Williamson DF, Vinicor F: Translation research for chronic disease: The case of diabetes. Diabetes Care 2000; 23:1794-1798.
7. Glasgow RE, Nutting PA, King DK, Nelson CC, Cutter G, Gaglio B, Rahm AK, Whitesides H, Amthauer H: A practical randomized trial to improve diabetes care. J Gen Intern Med 2004;19:1167-1174.
8. Kulasa KM, Henry RR: Pharmacotherapy of hyperglycemia. Expert Opin Pharmacother 2009;10:2415-2432.
9. Garg SK: The role of basal insulin and glucagon-like peptide- 1 agonists in the therapeutic management of type 2 diabetes-a comprehensive review. Diabetes Technol Ther 2010;12:11-24.
10. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-2637.
11. Scott R, Wu M, Sanchez M, Stein P: Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61:171-180.
12. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS: Sitagliptin in clinical practice: A new approach in the treatment of type 2 diabetes. Expert Opin Pharmacother 2008; 9:1705-1720.
13. Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, Suzuki H, Hirayama Y, Ahmed T, Davies MJ, Stein PP: Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79:291-298.
14. Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, Amatruda JM, Stein PP, Kaufman KD: Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009;83: 106-116.
15. Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group: Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959-969.
16. Williams-Herman D, Johnson J, Teng R, Luo E, Davies MJ, Kaufman KD, Goldstein BJ, Amatruda JM: Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: A 54-week study. Curr Med Res Opin 2009;25:569-583.
17. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-1568.
18. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-745. (Pubitemid 47261855)
19. Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, Whicher D, Schwartz JS: Rethinking randomized clinical trials for comparative effectiveness research: The need for transformational change. Ann Intern Med 2009;151:206-209.
20. Riddle MC: Timely initiation of basal insulin. Am J Med 2004;116(Suppl 3A):3S-9S.
21. Deepa M, Farooq S, Deepa R, Manjula D, Mohan V: Prevalence and significance of generalized and central body obesity in an urban Asian Indian population in Chennai, India (CURES: 47). Eur J Clin Nutr 2009;63:259-267.
22. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
23. American Diabetes Association: Standards of medical care in diabetes-2010. Diabetes Care 2010;33(Suppl 1):S11-S61.
24. Ramachandran A, Snehalatha C, Vijay V: Low risk threshold for acquired diabetogenic factors in Asian Indians. Diabetes Res Clin Pract 2004;65:189-195.
25. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme (IDPP): The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289-297.
26. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
27. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006;368:1096-1105.
28. Ramachandran A, Snehalatha C, Mary S, Selvam S, Kumar CK, Seeli AC, Shetty AS: Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: Results of the Indian Diabetes Prevention Programme- 2 (IDPP-2). Diabetologia 2009;52:1019-1026.
29. Hollander PA, Kushner P: Type 2 diabetes comorbidities and treatment challenges: Rationale for DPP-4 inhibitors. Postgrad Med 2010;122:71-80.
30. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-2643.
31. Scheen AJ, Van Gaal LF: Sugar: Results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes. Rev Med Liege 2010;65:127-132.
32. Williams-Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ, Amatruda JM: Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:442-451.
33. Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein PP, Kaufman KD, Amatruda JM; Sitagliptin Study 024 Group: Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: A 2-year study. Int J Clin Pract 2010;64:562-576.
34. Riche DM, East HE, Riche KD: Impact of sitagliptin on markers of beta-cell function: A meta-analysis. Am J Med Sci 2009;337:321-328.
35. Peters AL: Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk. Cleve Clin J Med 2009;76(Suppl 5):S20-S27.
36. Pi-Sunyer FX: The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. Postgrad Med 2008;120:5-17.
37. Cryer PE: Hypoglycaemia: The limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002;45:937-948.